Paper Information

Title:  HDL THERAPY: ADDRESSING RESIDUAL RISK IN TREATING CAD
Type: PAPER
Author(s): MASKON OTEH*
 
 *MALAYSIA
 
Name of Seminar: INTERNATIONAL CONGRESS OF METABOLIC SYNDROME, OBESITY & DIABETES
Type of Seminar:  CONGRESS
Sponsor: 
Date:  2010Volume 2
 
 
Abstract: 

UNDERSTANDING THE STRUCTURE AND METABOLISM OF HDL IS ESSENTIAL FOR COMPREHENSIVE MANAGEMENT OF DYSLIPIDAEMIA. EPIDEMIOLOGICAL STUDIES HAVE ESTABLISHED THE RELATIONSHIP OF LOW-HDL WITH INCREASED INCIDENCE OF CORONARY ARTERY DISEASE. HOWEVER, THUS FAR, LESS CERTAINTY IS OBSERVED ON THE EFFECT OF HDL REDUCING THERAPY IN THE SUBSEQUENT REDUCTION OF CAD. HDL RAISING CAN BE OBTAINED VIA DIETARY, EXERCISE AND OTHER NON-PHARMACOLOGICAL MEANS. PHARMACOLOGICAL TREATMENT AVAILABLE CURRENTLY ARE NICOTINIC ACID, FIB RATE AND STATINS (EITHER AS MONOTHERAPY OR COMBINATION). THERE ARE OTHER AGENTS THAT HAVE BEEN SHOWN TO INCREASE HDL, UNFORTUNATELY WITH PARADOXICAL OUTCOMES. IN SHORT, CURRENT TREATMENT OF LOW HDL IS STILL FAR FROM SATISFACTORY. HOWEVER, TREATING THE OVERALL PROFILE OF DYSLIPIDAEMIA (INCLUDING TARGETING THE LDL AND TG) HAS BEEN PROVEN TO BE MORE PRODUCTIVE.

 
Keyword(s): 
 
Yearly Visit 9  
 
Latest on Blog
Enter SID Blog